HopeStage
Back to all studies
CompletedNCT01593774

Melatonin to Study Metabolic Side Effects of Olanzapine

About this titleRead the official source — NCT01593774
Medication studyAges 18–65IranSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateMay 2012
Recruitment status
Completed
Enrollment listed in the registry
36
Sponsor
Guilan University of Medical Sciences
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Iran
Age range
From 18 Years to 65 Years
Official registry ID
NCT01593774
Official title
Show the full official title

Phase 2 Study of Melatonin Adjunct to Olanzapine for Prevention of Olanzapine-associated Metabolic Side Effects.

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Rasht

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Guilan University of Medical Sciences, a university.

Did this study involve medication?

Yes. The study involved medication, including Melatonin and Placebo.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies